Expert interview with Carl June
EHA Learning Center, Carl June, 221457
Expert interview with Marion Subklewe
EHA Learning Center, Marion Subklewe, 225610
Expert interview with Sara Gorashian
EHA Learning Center, Sara Gorashian, 225609
Expert interview with Jyoti Nangalia
EHA Learning Center, Jyoti Nangalia, 225608
Amyloidosis: The rapidly changing face of diagnosis and therapy in AL amyloidosis
EHA Learning Center, Giampaolo Merlini, 219242
Treating Thalassemia: Thinking 'out of the box'
EHA Learning Center, Stefano Rivella, 219243
Normal and leukemic hematopoiesis in the bone marrow. Metabolic regulation in a dynamic environment
EHA Learning Center, Tsvee Lapidot, 219244
ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY
EHA Learning Center, Meletios A Dimopoulos, 218888
CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Steffen Boettcher, 218887
THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB
EHA Learning Center, Rocco Piazza, 218886
RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS
EHA Learning Center, Jong Wook Lee, 218885
From epidemiology to treatment decisions (the role of T cell registries)
EHA Learning Center, Massimo Federico, 219234
PTCL: Evidence for subtype specific treatment approaches?
EHA Learning Center, F D'Amore, 219235
NK/T cell lymphoma: Novel insights, novel therapies?
EHA Learning Center, Won Seog Kim, 219236
HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY
EHA Learning Center, Lydia Scarfo, 218883
HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY
EHA Learning Center, Lydia Scarfo, 219219
MAPPING THE THREE-DIMENSIONAL GENOME DYNAMICS IN NORMAL AND NEOPLASTIC B CELLS
EHA Learning Center, Iñaki Martin-Subero, 219220
RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS
EHA Learning Center, Jong Wook Lee, 219221
THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB
EHA Learning Center, Rocco Piazza, 219222
CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Steffen Boettcher, 219223
ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY
EHA Learning Center, Meletios A Dimopoulos, 219224
Mechanisms underlying oncogenic transcription factors in ALL
EHA Learning Center, Jan Cools, 219226
Novel genetic subgroups in acute lymphoblastic leukemia
EHA Learning Center, Christine Harrison, 219227
Current concepts in ALL frontline trials in children and young adults
EHA Learning Center, Mats Heyman, 219228
Single cell genomics in CML
EHA Learning Center, Adam Mead, 219230
Immune targeting of CML to improve treatment outcome
EHA Learning Center, Andreas Burchert, 219231
TFR treatment goal for all CML patients
EHA Learning Center, Delphine Rea, 219232
Future prospects for the treatment of hemophilia: A global perspective
EHA Learning Center, David Lillicrap, 219238
Monoclonal antibody-based therapies
EHA Learning Center, Midori Shima, 219239
Modified FVIII and FIX recombinant products
EHA Learning Center, Elena Santagostino, 219240
Treating thalassemia with iron restriction
EHA Learning Center, Stefano Rivella, 223400
Is getting old bad?
EHA Learning Center, Michael Heuser, 223399
CAR -T cell therapy: Here to say?
EHA Learning Center, Peter Borchmann, 223398
The best treatment for SAA?
EHA Learning Center, Jakob R Passweg, 223397
Anemia in the elderly: is it real?
EHA Learning Center, Domenico Girelli, 223396
Iron Metabolism: what do you need to know?
EHA Learning Center, Tomas Ganz, 223395
Marginal Zone Lymphona: from diagnosis to treatment
EHA Learning Center, Catherine Thieblemont, 223394
Microenvironment in MPN
EHA Learning Center, Simon Mendez-Ferrer, 219198
Inflammation and anti-inflammatory approaches in MPN
EHA Learning Center, Steffen Koschmieder, 219199
Stem cell transplantation for myelofibrosis
EHA Learning Center, Nicolaus Kröger, 219200
Which are the preferred treatment combinations and sequence(s): In the transplant eligible / In the elderly
EHA Learning Center, Hartmut Goldschmidt, 219201
What are the treatment goals and optimal endpoints in RRMM
EHA Learning Center, Thierry Facon, 219202
How I manage extramedullary disease and plasma cell leukemia
EHA Learning Center, María-Victoria Mateos, 219203
Biology of secondary leukemia
EHA Learning Center, Timothy Graubert, 219205
Impact of underlying disease on secondary leukemia
EHA Learning Center, Lene Sofie Granfeldt Østgård, 219206
Prognostic factors and treatment options in secondary leukemia
EHA Learning Center, Maria Teresa Voso, 219207
Precision hematology: Implementing genomic profiling at national level
EHA Learning Center, Richard Rosenquist, 219209
Towards a molecular classification of Philadelphia- negative myeloproliferative neoplasms
EHA Learning Center, Radek Skoda, 219210
Molecular characterization as a basis for novel treatment paradigms in AML
EHA Learning Center, Hartmut Döhner, 219211
Assessing MRD in multiple myeloma
EHA Learning Center, Hervé Avet-Loiseau, 219212
New immunomodulators - New infectious diseases mind set?
EHA Learning Center, Sibylle Mellinghoff, 219214
Aspergillus resistance: Time to change the antifungal approach?
EHA Learning Center, Katrien Lagrou, 219215
One size does not fit all: Improving outcomes with personalized infection management?
EHA Learning Center, Martin Hönigl, 219216
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF DARBEPOETIN ALFA FOR THE TREATMENT OF ANEMIC PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
EHA Learning Center, Esther Natalie Oliva, 214478
OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PRIOR BLINATUMOMAB IN ZUMA-3, A STUDY OF KTE-C19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
EHA Learning Center, Olalekan O. Oluwole, 214484
CHEMOTHERAPY AND VENETOCLAX IN ELDERLY AML TRIAL (CAVEAT): A PHASE 1B DOSE ESCALATION STUDY EXAMINING MODIFIED INTENSIVE CHEMOTHERAPY IN FIT ELDERLY PATIENTS
EHA Learning Center, Andrew Wei, 214491
TP53 MUTATION HAD A NEGATIVE PROGNOSTIC IMPACT IN UNTREATED YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AT HIGH-RISK: A SUB-ANALYSIS OF FIL-DLCL04 STUDY
EHA Learning Center, Annalisa Chiappella, 214569
GENOMIC ALTERATIONS IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA FREQUENTLY AFFECT CELL CYCLE KEY REGULATORS AND NOTCH1 REGULATED TRANSCRIPTION.
EHA Learning Center, Jennifer Edelmann, 214583
THE FREQUENCY OF THE ETHNIC NEUTROPENIA-ASSOCIATED RS2814778 SNP OF DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES (DARC) GENE IN A COHORT OF EUROPEAN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA
EHA Learning Center, Helen Papadaki, 214588
NOVEL INSIGHTS INTO SPLEEN INJURY DURING THE FIRST 2 YEARS OF LIFE IN SCA CHILDREN: A LONGITUDINAL STUDY
EHA Learning Center, Sara El Hoss, 214590
SINGLE-CELL PROFILING REVEALS KEY DIFFERENCES IN THE CELLULAR ARCHITECTURE OF HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS THROUGHOUT FETAL AND ADULT LIFE
EHA Learning Center, Anindita Roy, 214591
THE MUTATIONAL LANDSCAPE IN HYDROXYCARBAMIDE-RESISTANT/INTOLERANT ESSENTIAL THROMBOCYTHEMIA TREATED ON THE MAJIC-ET STUDY
EHA Learning Center, Jennifer O'Sullivan, 214619
PRECLINICAL EVALUATION OF THE NEW BCMAXCD3 BISPECIFIC ANTIBODY JNJ-957 FOR THE TREATMENT OF MULTIPLE MYELOMA
EHA Learning Center, Kristine Frerichs, 214621
PHASE 1B/2 COMBINATION STUDY OF APR-246 AND AZACITIDINE (AZA) IN PATIENTS WITH TP53 MUTANT MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, David Sallman, 214477
DURABLE RESPONSE WITH VENETOCLAX IN COMBINATION WITH DECITABINE OR AZACITADINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Courtney D. DiNardo, 214482
PERSISTENT BCR-ABL1 CLONAL HEMATOPOIESIS AFTER BLAST CLEARANCE IDENTIFIES A CML-LIKE SUBGROUP OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ALL: INTERIM RESULTS FROM THE GRAAPH-2014 TRIAL
EHA Learning Center, Emmanuelle Clappier, 214483
FAVOURABLE OUTCOMES WITH R-CODOX-M/R-IVAC ACROSS ALL SUBGROUPS OF AGGRESSIVE HIGH GRADE B-CELL LYMPHOMA: PATHOLOGY AND UPDATED SURVIVAL RESULTS FROM A PHASE 2 UK NCRI/LLR TRIAL
EHA Learning Center, Elizabeth Phillips, 214487
SIMULTANEOUS TARGETING OF MCL-1 (S63845) AND BCL-2 (VENETOCLAX) ANTI-APOPTOTIC PROTEINS IN MULTIPLE MYELOMA
EHA Learning Center, Esperanza Algarín, 214498
PERIVASCULAR NICHE CELLS SENSE THROMBOCYTOPENIA AND ACTIVATE PLATELET-BIASED HSCS IN AN IL-1 DEPENDENT MANNER
EHA Learning Center, Tiago Cunha Luis, 214499
THE COMBINATION OF THE MDM2 ANTAGONIST, IDASANUTLIN WITH NILOTINIB TARGETS PRIMITIVE CHRONIC MYELOID LEUKEMIA (CML) CELLS IN VITRO AND IN VIVO.
EHA Learning Center, Mary Scott, 214573
GROWTH DYNAMICS IN NATURALLY PROGRESSING CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Michaela Gruber, 214582
PROGNOSTIC FACTORS FOR HLH IN ADULTS – ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE
EHA Learning Center, Rafal Machowicz, 214623
GENOME WIDE ASSOCIATION STUDIES (GWAS) OF CEREBROVASCULAR EVENTS IN PATIENTS WITH SICKLE CELL ANAEMIA (SCA)
EHA Learning Center, John Brewin, 214626
IMETELSTAT IN RBC TRANSFUSION-DEPENDENT (TD) LOWER RISK MDS RELAPSED/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESA) (IMERGE): UPDATED EFFICACY AND SAFETY
EHA Learning Center, Pierre Fenaux, 214476
MUTANT IDH (MIDH) INHIBITORS, IVOSIDENIB OR ENASIDENIB, WITH AZACITIDINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Courtney D. DiNardo, 214481
MS4A3 REGULATES CELL SURFACE CYTOKINE RECEPTOR EXPRESSION, DIFFERENTIATION, AND DRUG RESISTANCE IN CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Anna Eiring, 214572
GENOME-WIDE ASSOCIATION STUDY REVEALS ANKYRIN REPEAT AND SOCS BOX PROTEIN 3 (ASB3) AND INOSITOL POLYPHOSPHATE MULTIKINASE (IPMK) AS NEW RISK LOCI FOR RELAPSE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Laura Hinze, 214578
EFFECTS OF DARATUMUMAB ON THE COMPOSITION AND ACTIVATION STATUS OF IMMUNE-CELL POPULATIONS IN CENTAURUS, A PHASE 2 RANDOMIZED STUDY OF SMOLDERING MULTIPLE MYELOMA (SMM) PATIENTS
EHA Learning Center, Homer Adams III, 214585
MANAGEMENT OF ELANE-NEUTROPENIA: LIFETIME G-CSF VS HAEMATOPOIETIC STEM CELL TRANSPLANTATION LEARNING LESSON FROM THE EXPERIENCE
EHA Learning Center, Francesca Fioredda, 214587
1 INTRAVASCULAR HEMOLYSIS INDUCES COMPLEMENT SYSTEM ACTIVATION MEDIATED BY HEME AND HEME-LOADED ERYTHROCYTE MICROVESICLES
EHA Learning Center, Lubka Roumenina, 214589
IMPACT OF CONCURRENT FOLLICULAR LYMPHOMA OR OTHER LOW-GRADE B-CELL LYMPHOMA ON THE CLINICAL OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Yucai Wang, 214618
OVEREXPRESSION OF THE TRANSCRIPTION FACTOR CDX2 IN HAEMATOPOIETIC STEM CELLS PREDISPOSES TO HAEMATOLOGICAL MALIGNANCIES
EHA Learning Center, Therese Vu, 214629
INTEGRATED ATAC-SEQ AND SINGLE-CELL SYNERGISTIC CHEMOSENSITIVITY PROFILING IDENTIFIES RATIONAL DRUG COMBINATIONS IN IBRUTINIB-TREATED CLL PATIENTS
EHA Learning Center, Gregory Vladimer, 214638
ENASIDENIB MONOTHERAPY IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH PREVIOUSLY UNTREATED MUTANT-IDH2 (MIDH2) ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Daniel A. Pollyea, 214480
SURVIVAL OF VERY ELDERLY PATIENTS WITH DLBCL ACCORDING TO TREATMENT INTENSITY IN THE RITUXIMAB ERA: A SWEDISH LYMPHOMA REGISTRY STUDY
EHA Learning Center, Kristina Sonnevi, 214568
JAK1-STAT3 SIGNALING AXIS SUPPORTS LEUKEMIC STEM CELL PERSISTENCE IN CML
EHA Learning Center, Mirle Schemionek, 214571
A RANDOMIZED PHASE II STUDY OF STANDARD DOSE AZACITIDINE ALONE OR IN COMBINATION WITH LENALIDOMIDE IN HIGH-RISK MDS WITH A KARYOTYPE INCLUDING DEL(5Q)
EHA Learning Center, Bengt Rasmussen, 214575
A NOVEL, INTEGRATED AND VALIDATED PROGNOSTIC INDEX FOR PREDICTING OUTCOME IN ACUTE LYMPHOBLASTIC LEUKAEMIA PROVIDES NEW APPROACH FOR RISK STRATIFICATION.
EHA Learning Center, Anthony Moorman, 214577
CLINICAL IMPORTANCE OF DNA METHYLATION SIGNATURES IN CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS TREATED WITH CHEMO-IMMUNOTHERAPY
EHA Learning Center, J.C. Strefford, 214580
EXPRESSION OF PROTEINS IN CD138+ PLASMA CELLS PREDICTS PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VRD REGIMEN.
EHA Learning Center, Irena Misiewicz-Krzeminska, 214584
CHARACTERIZATION OF ORALLY BIOAVAILABLE SMALL MOLECULE INHIBITORS OF COMPLEMENT C5
EHA Learning Center, Alonso Ricardo, 214586
THE EFFECT OF COMPLEMENT INHIBITOR CP40 ON ERYTHROCYTE DESTRUCTION IN AIHA
EHA Learning Center, Inge Baas, 214625
P53 DEFICIENCY DRIVES LEUKEMIC TRANSFORMATION OF HEMATOPOIETIC STEM CELLS BY MAINTAINING QUIESCENCE IN RESPONSE TO DNA DAMAGE
EHA Learning Center, Andreas Brown, 214628
IVOSIDENIB (AG-120) IN MUTANT IDH1 RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS OF A PHASE 1 STUDY
EHA Learning Center, Daniel A. Pollyea, 214479
RADIOTHERAPY TO BULKY AND EXTRALYMPHATIC DISEASE IN COMBINATION WITH 6XR-CHOP-14 OR R-CHOP-21 IN YOUNG GOOD-PROGNOSIS DLBCL PATIENTS: RESULTS OF THE 2X2 RANDOMIZED UNFOLDER TRIAL OF THE DSHNHL/GLA
EHA Learning Center, Michael Pfreundschuh, 214567
THE TUMOR SUPPRESSOR MIR-300 PRESERVES CANCER STEM CELLS AND INHIBITS NK CELL ANTICANCER IMMUNITY
EHA Learning Center, Danilo Perrotti, 214570
A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME
EHA Learning Center, Guillermo Garcia-Manero, 214574
OUTCOMES OF YOUNG ADULT (≥ 18-25 YEARS) AND PEDIATRIC (<18 YEARS) PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING TREATMENT WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
EHA Learning Center, Susana Rives, 214576
THE CHRONOLOGICAL ORDER OF COPY NUMBER CHANGES IN HYPERDIPLOID MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Francesco Maura, 214620
A COHORT OF 22 PATIENTS WITH SAMD9/SAMD9L DISORDER: BONE MARROW FAILURE AND MDS PREDISPOSITION WITH TRANSIENT MONOSOMY 7
EHA Learning Center, Marie Sébert, 214622

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings